FFA
GALT icon

First Foundation Advisors’s Galectin Therapeutics GALT Stock Holding History

First Foundation Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18,240
Closed -$63K – 351
2018
Q4 		$63K Sell
18,240
-227,500
-93% -$1.09M ﹤0.01% 370
2018
Q3 		$1.48M Buy
+245,740
New +$1.35M 0.08% 135

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

First Foundation Advisors's GALT Position: Q1 2019 in Review

First Foundation Advisors sold out of Galectin Therapeutics (GALT) in Q1 2019, closing a stake of 18,240 shares — an estimated $63K sold.

First Foundation Advisors first reported a position in GALT in Q3 2018 and held it in 2 quarters. The position peaked at $1.48M in Q3 2018. 65 funds tracked by Wall St. Rank hold GALT as of Q1 2019.

  • First Foundation Advisors reported no remaining Galectin Therapeutics position as of Q1 2019 after selling out during the quarter.
  • First Foundation Advisors sold 18,240 Galectin Therapeutics shares in Q1 2019, an estimated $63K.
  • First Foundation Advisors first reported a position in Galectin Therapeutics in Q3 2018 and held it in 2 quarters.
  • First Foundation Advisors's Galectin Therapeutics position peaked at $1.48M in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2019.

Based on First Foundation Advisors's 13F filing for Q1 2019, filed 13 May 2019.